We are live on ! Find out more
CTMX icon

CytomX Therapeutics

126 hedge funds and large institutions have $249M invested in CytomX Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 43 increasing their positions, 51 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.45% more ownership

Funds ownership: 79.76%82.21% (+2.4%)

2% more capital invested

Capital invested by funds: $243M → $249M (+$5.62M)

3% less funds holding

Funds holding: 130126 (-4)

16% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 51

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

Holders
126
Holders Change
-4
Holders Change %
-3.08%
% of All Funds
2.23%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
43
Reduced
51
Closed
15
Calls
$88K
Puts
Net Calls
+$88K
Net Calls Change
+$22K
Name Holding Trade Value Shares
Change
Change in
Stake
PP
51
PDT Partners
New York
$553K -$169K -23,664 -22%
AA
52
ALPS Advisors
Colorado
$547K +$596K +83,493 New
Prudential Financial
53
Prudential Financial
New Jersey
$544K -$521K -72,900 -47%
JP Morgan Chase
54
JP Morgan Chase
New York
$528K -$84.2K -11,781 -13%
JCIA
55
Jackson Creek Investment Advisors
Colorado
$526K -$979 -137 -0.2%
HP
56
Harbourvest Partners
Massachusetts
$519K
Squarepoint
57
Squarepoint
New York
$503K +$272K +38,065 +98%
MCM
58
Moore Capital Management
New York
$491K
GC
59
Globeflex Capital
California
$455K
California State Teachers Retirement System (CalSTRS)
60
California State Teachers Retirement System (CalSTRS)
California
$446K
AllianceBernstein
61
AllianceBernstein
Tennessee
$412K
State of Wisconsin Investment Board
62
State of Wisconsin Investment Board
Wisconsin
$405K -$55K -7,700 -11%
RhumbLine Advisers
63
RhumbLine Advisers
Massachusetts
$387K +$23.6K +3,310 +6%
Connor, Clark & Lunn Investment Management (CC&L)
64
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$383K +$251K +35,092 +150%
New York State Common Retirement Fund
65
New York State Common Retirement Fund
New York
$341K -$99.3K -13,900 -21%
Tudor Investment Corp
66
Tudor Investment Corp
Connecticut
$340K -$336K -47,068 -48%
FQ
67
First Quadrant
California
$335K -$58.6K -8,201 -14%
UBS AM
68
UBS AM
Illinois
$323K
ECM
69
ExodusPoint Capital Management
New York
$273K +$88.3K +12,365 +42%
SEI Investments
70
SEI Investments
Pennsylvania
$258K -$489K -68,456 -64%
CSS
71
Cubist Systematic Strategies
Connecticut
$248K +$98.6K +13,803 +57%
VEA
72
Virtus ETF Advisers
New York
$245K -$9.84K -1,378 -4%
GCP
73
GSA Capital Partners
United Kingdom
$209K +$25.7K +3,603 +13%
EAM
74
Exane Asset Management
France
$200K -$238K -33,252 -52%
Manulife (Manufacturers Life Insurance)
75
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$197K +$17.5K +2,449 +9%

CTMX Hedge Fund Activity: Q4 2020 in Review

126 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2020, worth a combined $249M — up 2.3% from $243M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of CTMX and 11 opened new positions — a net loss of 4 holders — while 51 trimmed existing stakes and 43 added.

The largest buyer was BVF Inc, adding an estimated $14.4M. The largest seller was First Manhattan, exiting entirely with an estimated $2.3M sold.

  • 126 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2020, down from 130 in Q3 2020.
  • Funds reported $249M of CytomX Therapeutics stock for Q4 2020, up 2.3% quarter-over-quarter.
  • 11 funds opened new CytomX Therapeutics positions in Q4 2020 and 15 closed out, a net change of -4 holders.
  • The largest CytomX Therapeutics buyer in Q4 2020 was BVF Inc, an estimated $14.4M added.
  • The largest CytomX Therapeutics seller in Q4 2020 was First Manhattan, an estimated $2.3M sold.

Based on aggregated 13F filings for Q4 2020.